UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000006551
Receipt number R000007763
Scientific Title Budesonide/formoterol combination therapy versus budesonide plus tulobuterol-patch therapy in elderly asthmatic patients: A randomized, comparative study
Date of disclosure of the study information 2011/10/17
Last modified on 2017/04/24 11:13:01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Budesonide/formoterol combination therapy versus budesonide plus tulobuterol-patch therapy in elderly asthmatic patients: A randomized, comparative study

Acronym

A comparative study of budesonide/formoterol combination therapy in elderly asthmatic patients

Scientific Title

Budesonide/formoterol combination therapy versus budesonide plus tulobuterol-patch therapy in elderly asthmatic patients: A randomized, comparative study

Scientific Title:Acronym

A comparative study of budesonide/formoterol combination therapy in elderly asthmatic patients

Region

Japan


Condition

Condition

Bronchial Asthma

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the efficacy and safety of budesonide/formoterol combination therapy with budesonide plus tulobuterol-patch therapy in elderly asthmatic patients

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Improvement in the ACQ(asthma control questionnaire) score after 12 weeks

Key secondary outcomes

Change of various indicator as follow
1) Fraction of exhaled Nitric Oxide
2) Lung function(FEV1.0 etc)
3) Asthma relevant QOL (miniAQLQ score)
4) Night-time awaking due to asthma
5) Symptom-free days


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Budesonide/formoterol group
Symbicort Turbuhaler 160/4.5ug two inhalations, twice daily for 12 weeks

Interventions/Control_2

Budesonid + turobuterol-patch group Pulmicort Turbuhaler 200ug two inhalations, twice daily + tulobuterol-patch (1 or 2mg) once daily for 12 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

65 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Signed informed consent
2) Outpatients over 65 years old with asthma
3) Who have been using Adoair 50/100ug or 50/250ug one inhalation twice daily or ICS (low or moderate dose) at least for over 4 weeks
4) ACQ > 0.75 or %FEV1pred < 80%

Key exclusion criteria

1) Patients with a history of hypersensitivity(e.g contact dermatitis) to any ingredient contained in the budesonide/formoterol combination
2) Patients with a history of hypersensitivity to any ingredient contained in the tulobuterol-patch
3) Patients with infectious with no availabl effective antimicrobial drugs or with deep-seated mycosis
4) Patients with other respiratory illnesses(lung cancer, tuberculosis, bronchiectasis etc)
5) Patients with heart failure
6) Patients with RE
7) %FEV1<60%
8) Patients who contracted a respiratory infection that could influence asthma within the last 4 weeks
9) Patients who were treated with systemic corticosteroids in the last 4 weeks
10) Patients who are taking high-dose ICS
11) Patients who are taking PSL
12) Patients who are taking inhaled anticholinergic drugs
13) Patients who are treated with ZOREA(omalizumab)
14) Patients with other severe diseases
15) Patients who are considered inappropriate by the physician in charge

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hiroto Matsuse

Organization

Nagasaki University Hospital

Division name

Second Department of Internal Medicine

Zip code


Address

1-7-1, Sakamoto, Nagasaki, Japan

TEL

095-819-7273

Email

midukipapa2002@yahoo.co.jp


Public contact

Name of contact person

1st name
Middle name
Last name Tetsuya Kawano

Organization

Nagasaki University Hospital

Division name

Second Department of Internal Medicine

Zip code


Address

1-7-1, Sakamoto, Nagasaki, Japan

TEL

095-819-7273

Homepage URL


Email

midukipapa2002@yahoo.co.jp


Sponsor or person

Institute

Second Department of Internal Medicine, Nagasaki University Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

長崎大学病院(長崎県)


Other administrative information

Date of disclosure of the study information

2011 Year 10 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 09 Month 30 Day

Date of IRB


Anticipated trial start date

2011 Year 10 Month 01 Day

Last follow-up date


Date of closure to data entry

2016 Year 03 Month 31 Day

Date trial data considered complete

2016 Year 03 Month 31 Day

Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 10 Month 17 Day

Last modified on

2017 Year 04 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007763


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name